v3.26.1
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
Revenue
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Customer A25 %23 %25 %23 %
Customer B17 %16 %19 %17 %
Customer C***10 %
Customer D*10 %**

Accounts Receivable, Net
June 30, 2026December 31, 2025
Customer A18 %23 %
Customer B32 %19 %
Customer C*14 %
Schedule of Disaggregation of Revenue
The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue:
Commercial$10,352 $8,811 $19,828 $17,571 
Government5,206 3,926 9,487 7,633 
Client direct bill(1)4,275 4,371 7,725 7,367 
Other(2)108 94 207 129 
Total revenue$19,941 $17,202 $37,247 $32,700 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay.
Schedule of Cash and Cash Equivalents
Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):
 
June 30, 2026December 31, 2025
Cash and cash equivalents$24,588 $32,220 
Restricted cash200 200 
Total cash, cash equivalents and restricted cash$24,788 $32,420 
Schedule of Restricted Cash and Cash Equivalents
Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):
 
June 30, 2026December 31, 2025
Cash and cash equivalents$24,588 $32,220 
Restricted cash200 200 
Total cash, cash equivalents and restricted cash$24,788 $32,420 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):
 
June 30, 2026June 30, 2025
Warrants to purchase common stock— 580,339 
Common stock options931,506 564,441 
Restricted stock units1,973,952 1,679,624 
Performance stock units800,000 — 
Employee stock purchase plan75,562 54,454 
Total3,781,020 2,878,858